ROSE for Improved Molecular Marker Testing Via EBUS
ROSE for Improved Molecular Marker Testing Via EBUS
Enrolling by invitation · NCT04945317 · Registry updated 2025-12-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ROSE for Improved Molecular Marker Testing Via EBUS | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Enrolling by invitation | Not applicable | 2025-12-17 | NCT04945317 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Johns Hopkins University | 579 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Johns Hopkins Bayview Medical Center | Baltimore | United States | 27 |
| Johns Hopkins Hospital | Baltimore | United States | 135 |
| Northwestern Medicine | Chicago | United States | 36 |
| The Medical University of South Carolina (MUSC) | Charleston | United States | 2 |